Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Klein Laboratories, Inc.
WARNING LETTER
•Klein Laboratories, Inc.•November 12, 2013

Klein Laboratories, Inc. – FDA Warning Letter, Nov 12, 2013

Record Details

On July 17, 2014, the FDA issued a Warning Letter to Klein Laboratories, Inc. following an inspection from August 22, 2013, to November 12, 2013. The inspection and review of the Osteojuv product label revealed serious violations of the Federal Food, Drug, and Cosmetic Act.

The FDA determined that Osteojuv is an unapproved new drug because its labeling claims, such as "Aggressively Target: ... Pain" and "Aggressively Target: ... Inflammation," indicate it is intended for disease treatment, mitigation, or prevention. As it is not generally recognized as safe and effective for these uses, it is considered a "new drug" under section 201(p) of the Act, requiring prior FDA approval for interstate commerce.

Even if not an unapproved new drug, Osteojuv is an adulterated dietary supplement due to numerous Current Good Manufacturing Practice (CGMP) violations (21 CFR Part 111). Key deficiencies include: 1. Failure to conduct identity testing for dietary ingredients (e.g., Glucosamine Sulfate, Chondroitin Sulfate, Hyaluronic Acid) and relying inadequately on supplier Certificates of Analysis. The firm's proposed methods (color, mesh, pH) were deemed insufficient for identity verification. 2. Failure to establish identity specifications for components. 3. Failure to establish product specifications

Company
Klein Laboratories, Inc.
Inspection date
November 12, 2013
Product type
Drugs
Office
New England District Office
Person
  • Mutahar Shamsi (District Director)
View Company Profile

ID · 9a4bde13-2360-489f-99d1-86b82c2cf4ce

Violation Codes10
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(p)21.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 342(g)(1)21 CFR 111.75(a)(1)(i)21 CFR 111.75(a)(2)(ii)21 CFR 111.70(b)21 CFR 111.70(b)(1)21 CFR 111.70(e)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Klein Laboratories, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.